Skip to main content
SpringerLink
Log in

Vertebral fracture efficacy during risedronate therapy in patients using proton pump inhibitors

  • Original Article
  • Published:
Osteoporosis International Aims and scope Submit manuscript

Abstract

Summary

Recent evidence suggests that proton pump inhibitor (PPI) use may affect fracture risk, an important issue for patients being concurrently treated for osteoporosis. The results of our post hoc analysis showed that, regardless of PPI concomitant use, risedronate significantly reduced the risk of new vertebral fractures compared with placebo.

Introduction

Recent evidence suggests that PPI use may affect fracture risk, an important issue for patients being concurrently treated for osteoporosis. Moreover, data suggest that concomitant use of PPIs may wane the anti-fracture effect of bisphosphonates. We explored the relationship between concomitant use of PPIs and incident vertebral fractures among patients treated with risedronate or placebo. Bone mineral density (BMD) and upper gastrointestinal (UGI) adverse events (AEs) were also assessed.

Methods

This study is a post hoc analysis of a subset of patients participating in three prospective, randomized, placebo-controlled clinical trials, with durations of up to 3 years, which evaluated the efficacy of risedronate in reducing fracture risk: Vertebral Efficacy with Risedronate Trial–MultiNational (VERT-MN); Vertebral Efficacy with Risedronate Trial–North America (VERT-NA); and the risedronate Hip Intervention Program (HIP).

Results

Total enrollment included 2,729 risedronate and 2,725 placebo patients. Concomitant acid-suppressing drugs were used by 8.8% of the total population (n = 482). Regardless of PPI concomitant use, risedronate significantly reduced the risk of new vertebral fractures compared with placebo (risk reduction: PPI users 57%, p = 0.009; PPI non-users 38%, p < 0.001). BMD increased with risedronate, independent of PPI use. PPI users were at a 2.5-fold greater risk of experiencing at least one UGI AE compared with non-users.

Conclusions

Risedronate significantly reduced the risk of new vertebral fractures compared with placebo, regardless of PPI concomitant use.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  1. Roughead EE, McGeechan K, Sayer GP (2004) Bisphosphonate use and subsequent prescription of acid suppressants. Br J Clin Pharmacol 57(6):813–816

    Article  PubMed  CAS  Google Scholar 

  2. Vestergaard P, Rejnmark L, Mosekilde L (2006) Proton pump inhibitors, histamine H2 receptor antagonists, and other antacid medications and the risk of fracture. Calcif Tissue Int 79(2):76–83

    Article  PubMed  CAS  Google Scholar 

  3. Yang YX, Lewis JD, Epstein S, Metz DC (2006) Long-term proton pump inhibitor therapy and risk of hip fracture. JAMA 296(24):2947–2953

    Article  PubMed  CAS  Google Scholar 

  4. de Vries F, Cooper A, Logan R, Cockle S, van Staa T, Cooper C (2007) Fracture risk in patients receiving concomitant bisphosphonate and acid-suppressive medication or bisphosphonate alone [abstract]. Osteoporos Int 18(Suppl 3):S261

    Google Scholar 

  5. Targownik LE, Lix LM, Metge CJ, Prior HJ, Leung S, Leslie WD (2008) Use of proton pump inhibitors and risk of osteoporosis-related fractures. CMAJ 179(4):319–326

    Article  PubMed  Google Scholar 

  6. Roux C, Briot K, Gossec L, Kolta S, Blenk T, Felsenberg D, Reid DM, Eastell R, Glüer CC (2009) Increase in vertebral fracture risk in postmenopausal women using omeprazole. Calcif Tissue Int 84(1):13–19

    Article  PubMed  CAS  Google Scholar 

  7. de Vries F, Cooper AL, Cockle SM, van Staa TP, Cooper C (2009) Fracture risk in patients receiving acid-suppressant medication alone and in combination with bisphosphonates. Osteoporos Int 20(12):1989–1998

    Article  PubMed  CAS  Google Scholar 

  8. Farina C, Gagliardi S (2002) Selective inhibition of osteoclast vacuolar H(+)-ATPase. Curr Pharma Des 8(23):2033–2048

    Article  CAS  Google Scholar 

  9. Tuukkanen J, Väänänen HK (1986) Omeprazole, a specific inhibitor of H(+)-K(+)-ATPase, inhibits bone resorption in vitro. Calcif Tissue Int 38(2):123–125

    Article  PubMed  CAS  Google Scholar 

  10. Mizunashi K, Furukawa Y, Katano K, Abe K (1993) Effect of omeprazole, an inhibitor of H+, K(+)-ATPase, on bone resorption in humans. Calcif Tissue Int 53(1):21–25

    Article  PubMed  CAS  Google Scholar 

  11. Wright MJ, Proctor DD, Insogna KL, Kerstetter JE (2008) Proton pump-inhibiting drugs, calcium homeostasis, and bone health. Nutr Rev 66(2):103–108

    Article  PubMed  Google Scholar 

  12. Schuler A (2007) Risks versus benefits of long-term proton pump inhibitor therapy in the elderly. Geriatr Nurs 28(4):225–229

    Article  PubMed  Google Scholar 

  13. O’Connell MB, Madden DM, Murray AM, Heaney RP, Kerzner LJ (2005) Effects of proton pump inhibitors on calcium carbonate absorption in women: a randomized crossover trial. Am J Med 118(7):778–781

    Article  PubMed  Google Scholar 

  14. Richards JB, Goltzman D (2008) Proton pump inhibitors: balancing the benefits and potential fracture risks. CMAJ 179(4):306–307

    Article  PubMed  Google Scholar 

  15. Reginster J, Minne HW, Sorensen OH, Hooper M, Roux C, Brandi ML, Lund B, Ethgen D, Pack S, Roumagnac I, Eastell R (2000) Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. Osteoporos Int 11(1):83–91

    Article  PubMed  CAS  Google Scholar 

  16. Harris ST, Watts NB, Genant HK, McKeever CD, Hangartner T, Keller M, Chesnut CH 3rd, Brown J, Eriksen EF, Hoseyni MS, Axelrod DW, Miller PD (1999) Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. JAMA 282(14):1344–1352

    Article  PubMed  CAS  Google Scholar 

  17. McClung MR, Geusens P, Miller PD, Zippel H, Bensen WG, Roux C, Adami S, Fogelman I, Diamond T, Eastell R, Meunier PJ, Reginster JY, Hip Intervention Program Study Group (2001) Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group. N Engl J Med 344(5):333–340

    Article  PubMed  CAS  Google Scholar 

  18. United States Food and Drug Administration (2010) http://www.fda.gov/. Accessed January 25, 2010

  19. Kaye JA, Jick H (2008) Proton pump inhibitor use and risk of hip fractures in patients without major risk factors. Pharmacotherapy 28(8):951–959

    Article  PubMed  CAS  Google Scholar 

  20. McGowan B, Bennett K, Barry M, Canny M (2008) The utilisation and expenditure of medicines for the prophylaxis and treatment of osteoporosis. Ir Med J 101(2):38–41

    PubMed  CAS  Google Scholar 

  21. Masud T, Watts N, Lindsay R, Bainbridge V, Lange J, Steinbuch M (2008) Initiation of PPI use in postmenopausal women treated with medications for chronic diseases [abstract]. Presented at the International Osteoporosis Foundation (IOF) World Congress on Osteoporosis, Bangkok, Thailand

    Google Scholar 

  22. Cryer B, Bauer DC (2002) Oral bisphosphonates and upper gastrointestinal tract problems: what is the evidence? Mayo Clin Proc 77(10):1031–1043

    Article  PubMed  Google Scholar 

  23. Ho PM, Maddox TM, Wang L, Fihn SD, Jesse RL, Peterson ED, Rumsfeld JS (2009) Risk of adverse outcomes associated with concomitant use of clopidogrel and proton pump inhibitors following acute coronary syndrome. JAMA 301(9):937–944

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgments

The authors received editorial/writing support in the preparation of this manuscript from The Alliance for Better Bone Health (an alliance between Warner Chilcott Company LLC and sanofi-aventis). Betty Thompson, PhD, from Excerpta Medica provided editorial and writing assistance. The authors are fully responsible for all content and editorial decisions and received no other financial support or other form of compensation related to the development of the paper.

Conflicts of interest

C. Roux has received honoraria and research grants from the Alliance for Better Bone Health. J. L. Goldstein has received research and/or educational grant funding, consulting fees, contract payments, and speaker’s honoraria from AstraZeneca, Given, Horizon, Logical Therapeutics, Novartis, Pfizer, POZEN, Takeda, and TAP; he has received consulting fees from Amgen, Astellas, GlaxoSmithKline, Merck, Novartis, PLX, Procter & Gamble, and Wyeth. Grants have been awarded from Amgen, Novartis, and GlaxoSmithKline and contract payments from Amgen and Glaxo SmithKline. X. Zhou and A. Klemes are employees of Procter & Gamble. R. Lindsay has served as a consultant for Amgen, Eli Lilly, Procter & Gamble, NPS, sanofi-aventis, Roche-GlaxoSmithKline, Novartis, and Wyeth.

Author information

Authors and Affiliations

  1. Department of Rheumatology, AP-HP Cochin Hospital, Paris Descartes University, 27 rue Faubourg Saint Jacques, Paris, 75014, France

    C. Roux

  2. Department of Medicine, University of Illinois at Chicago, Chicago, IL, USA

    J. L. Goldstein

  3. Procter & Gamble, Mason, OH, USA

    X. Zhou & A. Klemes

  4. Helen Hayes Hospital, West Havershaw, NY, USA

    R. Lindsay

Authors
  1. C. Roux
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. J. L. Goldstein
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. X. Zhou
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. A. Klemes
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. R. Lindsay
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to C. Roux.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Roux, C., Goldstein, J.L., Zhou, X. et al. Vertebral fracture efficacy during risedronate therapy in patients using proton pump inhibitors. Osteoporos Int 23, 277–284 (2012). https://doi.org/10.1007/s00198-011-1574-5

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00198-011-1574-5

Keywords

Search

Navigation